Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate AVLX-144 is a drug candidate for the treatment of ischemic stroke.
Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.
Avilex Pharma appoints Mark Treherne as its new CEO. Dr. Teherne has more than 25 years’ industrial R&D experience including leading neurodegeneration at Pfizer UK.
© Copyright 2019 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK